Ondine Biomedical’s Steriwave Innovation Recognized for Transforming Infection Prevention

Ondine Biomedical, Inc. ( (GB:OBI) ) has provided an update.

Ondine Biomedical Inc. announced that Dr. Stuart Bond from Mid Yorkshire Teaching NHS Trust received the President’s Award at the International Photodynamic Association’s World Congress for his pioneering use of Ondine’s Steriwave photodisinfection in the NHS. This innovation led to a 71% reduction in surgical site infections in knee and hip replacement surgeries, highlighting the potential of Steriwave as a cost-effective, resistance-free alternative to antibiotics, and positioning the NHS as a leader in antibiotic stewardship.

The most recent analyst rating on (GB:OBI) stock is a Buy with a £55.00 price target. To see the full list of analyst forecasts on Ondine Biomedical, Inc. stock, see the GB:OBI Stock Forecast page.

More about Ondine Biomedical, Inc.

Ondine Biomedical Inc. is a Canadian life sciences company specializing in light-activated antimicrobial therapies, known as photodisinfection, for preventing and treating infections, including those caused by multidrug-resistant organisms. The company has a range of investigational products based on its proprietary technology, with its nasal photodisinfection system, Steriwave®, approved in several countries and undergoing clinical trials in the US.

Average Trading Volume: 148,460

Technical Sentiment Signal: Buy

Current Market Cap: £46.54M

See more data about OBI stock on TipRanks’ Stock Analysis page.